Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 9/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917997 | 0.89 | SRD5A1 (0.39) | SRD5A1SRD5A2 | |
| SCHEMBL917874 | 0.89 | SRD5A1 (0.43) | SRD5A1SRD5A2 | |
| SCHEMBL917805 | 0.87 | SRD5A1 (0.46) | SRD5A1SRD5A2 | |
| SCHEMBL917798 | 0.87 | SRD5A1 (0.46) | SRD5A1SRD5A2 | |
| SCHEMBL916381 | 0.87 | SRD5A1 (0.42) | SRD5A1SRD5A2 | |
| SCHEMBL917242 | 0.86 | SRD5A1 (0.45) | SRD5A1SRD5A2 | |
| SCHEMBL917053 | 0.86 | SRD5A1 (0.45) | SRD5A1SRD5A2 | |
| SCHEMBL916849 | 0.86 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL917400 | 0.85 | SRD5A1 (0.44) | SRD5A1SRD5A2 | |
| SCHEMBL916570 | 0.85 | SRD5A1 (0.44) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6204273-B1 | TREATMENT OF ANDROGENIC SENSITIVE DISORDERS SUCH AS ACNE VULGARIS, SEBORRHEA, FEMALE HIRSUTISM, MALE PATTERN BALDNESS, AND BENIGN PROSTATIC HYPERPLASIA. | MERCK & CO., INC. | 2001-03-20 | — | — | US | disclosed |
| US-5910497-A | 16-pyrazinyl-substituted-4-aza-androstane 5-α-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1999-06-08 | — | — | US | disclosed |
| EP-0724592-B1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5739137-A | 16-substituted-4-aza-3-oxo-androstane as 5-alpha-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1998-04-14 | — | — | US | disclosed |
| US-5719158-A | 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |